Wuhan Institute of Virology, Chinese Academy of Sciences: orally administered nucleoside analog prodrug VV261 effectively inhibits the replication of Zika virus.

Research progress titled "Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus" was published by the team of researchers Xiao Gengfu/Zhang Lei from Wuhan Institute of Virology, Chinese Academy of Sciences, in collaboration with the team of researcher Shen Jingshan from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in the academic journal Signal Transduction and Targeted Therapy. The study identified a nucleoside prodrug VV261, which has entered clinical trials and can effectively inhibit Chikungunya virus replication. VV261 has previously entered phase I clinical trials for the treatment of Dengue virus infection, and this research provides important support for expanding the new indications of this candidate drug. The relevant experiments were conducted at the Wuhan National Biosafety Laboratory of the Chinese Academy of Sciences.